Market closedNon-fractional
FibroGen/FGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About FibroGen
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Ticker
FGEN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Francisco, United States
Employees
486
Website
www.fibrogen.com
FibroGen Metrics
BasicAdvanced
$72M
Market cap
-
P/E ratio
-$2.44
EPS
0.74
Beta
-
Dividend rate
Price and volume
Market cap
$72M
Beta
0.74
Financial strength
Current ratio
1.414
Quick ratio
1.236
Long term debt to equity
-81.744
Total debt to equity
-89.926
Interest coverage (TTM)
-13.70%
Management effectiveness
Return on assets (TTM)
-34.39%
Return on equity (TTM)
223.64%
Valuation
Price to revenue (TTM)
0.424
Price to book
-0.32
Price to tangible book (TTM)
-0.32
Price to free cash flow (TTM)
-0.258
Growth
Revenue change (TTM)
44.31%
Earnings per share change (TTM)
-25.20%
3-year revenue growth
-4.17%
3-year earnings per share growth
6.67%
What the Analysts think about FibroGen
Analyst Ratings
Majority rating from 3 analysts.
FibroGen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$56M
106.27%
Net income
-$33M
-41.46%
Profit margin
-58.85%
-71.62%
FibroGen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.90
-$0.65
-$0.57
-$0.33
-
Expected
-$0.70
-$0.68
-$0.43
-$0.42
-$0.32
Surprise
27.96%
-4.41%
34.12%
-21.43%
-
FibroGen News
AllArticlesVideos
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
GlobeNewsWire·1 month ago
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
GlobeNewsWire·1 month ago
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for FibroGen stock?
FibroGen (FGEN) has a market cap of $72M as of July 06, 2024.
What is the P/E ratio for FibroGen stock?
The price to earnings (P/E) ratio for FibroGen (FGEN) stock is 0 as of July 06, 2024.
Does FibroGen stock pay dividends?
No, FibroGen (FGEN) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next FibroGen dividend payment date?
FibroGen (FGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for FibroGen?
FibroGen (FGEN) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell FibroGen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.